Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia
Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia
Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV)
 infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained
 virological response rates (SVR12) above 90%. The objective of this study was to investigate
 the impact of DAA therapy on cryoglobulin clearance in patients with HCV-associated MC.
We focused on HCV patients with or without HIV with MC who had at least one cryoglobulin
 level assessment before and after DAA therapy and investigated the impact of DAA therapy on
 cryoglobulin clearance.
Inclusion Criteria:

 -  hepatitis C virus (HCV) infected patients

 -  symptomatic or asymptomatic mixed cryoglobulinemia

 -  coinfected or not with HIV

 -  treated by direct-acting antiviral (DAA) treatment

 -  at least one cryoglobulin measurement before and after DAA

 Exclusion Criteria:

 -